Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Nitric Oxide and Neuroprotection in Premature Infants
NCT00515281Phase 3Terminated
- Sponsor
- University of Chicago
- Start
- May 2008
- Primary completion
- Jun 2023
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nitric oxide in bronchopulmonary dysplasia (BPD) and neurodevelopmental disorder (NDD) (2 arms), sponsored by University of Chicago. Primary endpoints: Neurodevelopmental Outcome at 2 years and Bronchopulmonary Dysplasia or Death. Started May 2008; status: terminated.
02
Drugs
nitric oxide
03
Conditions
bronchopulmonary dysplasia (BPD)neurodevelopmental disorder (NDD)
Beyond the preview
Go deeper on NCT00515281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00515281.